Navigation Links
New Study Reveals Limitations of a Complex and Challenging Global,Tuberculosis Drug Marketplace

ately US$315 million per year, including high income country sales of the four first-line drugs commonly used to treat drug susceptible disease. Although researchers found that a number of factors limited the ability to estimate the global market for treatment for drug resistant disease, they were able to determine that US$54 million is spent annually on the more expensive, second-line treatments in the ten countries studied.

"Understanding how drugs actually reach patients is critical," said Nina Schwalbe, TB Alliance Director of Policy. "We know that desperately needed new cures that shorten and simplify TB treatment will only be effective if they are available to those who need them. This research offers valuable insights into what we at the TB Alliance and others will need to do to get new drug regimens to patients."

The TB Alliance is driving the advancement of the most comprehensive portfolio of TB drugs ever, and is accelerating discovery, preclinical and clinical research of known and novel classes of antibiotics to shorten and simplify TB treatment. The Alliance is committed to making all drugs developed by its research partnerships affordable, universally adopted, and available to all who need them.

The research for Pathway to Patients was conducted in partnership with IMS Health, Inc., a global strategic consulting group focused on the pharmaceutical and health care industries. The project was financed by a grant from the Netherlands Ministry of Foreign Affairs' Department of Development Cooperation (DGIS) and with the support of the Bill & Melinda Gates Foundation.

About TB Disease

Tuberculosis (TB), although curable, continues to kill someone somewhere in the world every 20 seconds -- about 4,400 people every day, or 1.6 million in 2005 alone, according to the latest estimates from the World Health Organization (WHO). TB is second only to HIV as the leading infectious killer of adults worldwide. It accounts for mor
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:1/15/2014)... DALLAS , Jan. 15, 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com ... to its store . (Photo: ... consumption upgrade and policy support, China,s ... the years, with total market size rising from 3.28 ...
(Date:1/15/2014)... the leading health care supply chain expertise, analytics and ... national contracts that expand its portfolio to provide hospital ... These include manufacturer product and service agreements, as well ... IT consulting support. New Novation agreements ...
(Date:1/15/2014)... BreedIT Corp (OTC: BRDT), through its Israeli ... sophisticated agro-breeding solutions for plant breeders and researchers, today ... of directors appointed chemistry and pharmaceutical industry expert Dr. ... the board. From 1975 to 2012, Dr. ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
(Date:4/24/2014)... is better to give than to receive at least ... study suggests. , The study found that 15- and 16-year-olds ... money to family members, are less likely to become depressed ... or keeping the money for themselves. , The researchers detail ... of Sciences . , The study focused on the ventral ...
(Date:4/24/2014)... Ore. An Oregon State University researcher has found ... of the symptoms of autism spectrum disorder in very ... be the first to show a direct relationship between ... fine and gross motor skills should be included in ... MacDonald, an assistant professor in OSU,s College of Public ...
(Date:4/24/2014)... led by a scientist at the University of York ... in the development of the nervous system may also ... cancer., A research team, led by Dr Will ... of Biology at York, has studied how voltage-gated sodium ... channels are found in the membranes of excitable cells, ...
(Date:4/23/2014)... Pregnant immigrants from Sub-Saharan Africa, Latin America ... pregnancy, according to new research from St. Michael,s ... British Journal of Obstetrics and Gynaecology , ... among immigrants and native-born women in six high-immigration ... Spain (Catalonia and Valencia) and the United States ...
(Date:4/23/2014)... director at the National Institute of Arthritis and Musculoskeletal ... recipient of the Ross Prize in Molecular Medicine, conferred ... Medicine . The award will be given on June ... Manhattan, followed by scientific presentations by Dr. O,Shea and ... Institutes of Health. , The award, which includes a ...
Breaking Medicine News(10 mins):Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Motor skill deficiencies linked to autism severity in new research 2Health News:Breast cancer replicates brain development process 2Health News:Pregnancy complications may be more common in immigrants from certain regions 2Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2
... Civility Mutual, based in,Santa Fe, New Mexico, launches ... offer education, training and CMEs for physician - ... tools and assessments their residents need to fulfill ... "Civility in health care begins with effective ...
... in materials such as paints, printing and dry ... and is thought to damage the central nervous ... attention and psychomotor function, frequently persists even after ... chronic solvent-induced encephalopathy (CSE). Although CSE is an ...
... profession employs more than 786,000 workers, CHICAGO, ... announced the release of its updated statistical map ... 2006" that details how,many employees, broken down into ... dental profession. The map also provides figures for ...
... Ala. -- Laboratory studies by University of Alabama ... investigational drug triphendiol (NV-196) causes cell death in ... tumor growth and sensitizes tumors to chemotherapy treatments. ... Ewan Tytler, Ph.D., assistant professor in the UAB ...
... becomes practical for treating human diseases, researchers must master ... at The Childrens Hospital of Philadelphia have advanced delivery ... bind to a variety of gene therapy vectors and ... genes at a disease site. , In an animal ...
... small business health,initiative but urges strengthened pre-existing ... The National Patient,Advocate Foundation (NPAF) today endorsed ... (SHOP), but called for stronger protections,to protect ... NPAF CEO and President Nancy Davenport-Ennis, "The ...
Cached Medicine News:Health News:New Health Care Company to Offer Training and CMEs on Physician - Patient Communications and Helps Fulfill ACGME Requirements 2Health News:Disturbances in brain circuitry linked to chronic exposure to solvents 2Health News:Academy of General Dentistry Releases Updated Employment Statistical Map 2Health News:UAB study shows investigational drug may treat biliary cancers 2Health News:In blood vessel stents, innovative materials allow better control, delivery of gene therapy 2Health News:In blood vessel stents, innovative materials allow better control, delivery of gene therapy 3Health News:Small Businesses and the Self-Employed Need Stronger Coverage Protections for Pre-Existing Conditions 2
... demanding smaller, higher performing systems specifically ... operational challenges. The new Philips HD11 ... for superb High Definition performance; elegant ... and a versatile suite of applications ...
... Ophthalmics introduces Tear Pool punctum plugs. Tear Pool ... silicone resin with no additives via a precision ... durometer rating, which is designed to facilitate insertion ... maintains its position in the punctum. The cap ...
The Cardiff Acuity Test is designed specifically for,acuity measurement in children aged 1 to 3 years. The,test is also helpful with other age groups with,intellectual impairment, dementia, hea...
... be the world wide sole distributor of ... from conventional drug eluting stents, the CONOR ... eluting stent designed to provide advanced drug ... release profiles to be tailored to optimize ...
Medicine Products: